Mostly Markets
Subscribe
Stocks/Health Care/Managed Health Care

HumanaHUM

Managed Health Care · Louisville, Kentucky · In the S&P 500
Solid businessPricier than peers
$414.50−0.52%After hours: $415.00 (+0.12%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 41.6% over 1 year
Humana over 1 yearDaily close, $, to 30 Oct 2026
$200$300Nov2026MarMayJulSep$414.50$200$300NovMarJul$414.50
Source: Nasdaq daily closes
Market value$49.77B
Price to earnings39.2x
Forward P/E33.1x
Dividend yield0.85%
Year to date+61.8%
One year+41.6%
Next earningsFri 6 Nov, before the open
SectorHealth Care
52-week range (closes)
$163.67$433.50

Quality and valuation

How Humana compares with other health care stocks. A description, not a recommendation.

Humana and 5 managed health care peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: pricier than most

An average business among health care companies, priced above most of them.

Humana trades at 33.1 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +14.1% vs +7.8%
  • Less profitable (operating margin): 1.8% vs 13.3%
  • Turns less of its sales into cash: 0.9% vs 15.9%
HUM trades at 33.1x forward earnings, above the sector medianForward p/e, Managed Health Care peers
NVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xHUM33.1xLLY36.3xSector median 19.1xNVS17.0xAZN17.5xMRK18.1xUNH18.9xABBV19.6xJNJ25.1xHUM33.1xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 44.3x earnings, HUM is pricier than its average since Apr 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
20x30x40xAverage 25.6x2025202644.3x20x40xAverage 25.6x2025202644.3x
Source: Nasdaq prices; SEC filings

Financials

From Humana's SEC filings, through the quarter ending 31 Mar 2026. Hover or tap a bar for its value.

Revenue grew 23.5% from a year earlierQuarterly revenue, $bn, latest Q1 ’26
$0bn$10bn$20bn$30bnQ2 ’24Q4 ’24Q2 ’25$39.6bnQ1 ’26$0bn$20bnQ2 ’24Q4 ’24Q2 ’25$39.6bnQ1 ’26
Source: SEC filings
Growth sped up to +23.5% last quarterRevenue growth, year on year, %
0%10%20%Q2 ’24Q4 ’24Q2 ’2523.5%Q1 ’260%10%20%Q2 ’24Q4 ’24Q2 ’2523.5%Q1 ’26
Source: SEC filings
Operating margin was 4.4% last quarterOperating income as a share of revenue, %
−2%0%2%5%Q2 ’24Q4 ’24Q2 ’254.4%Q1 ’260%5%Q2 ’24Q4 ’24Q2 ’254.4%Q1 ’26
Source: SEC filings
Free cash flow was $1.3 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$-1bn$0bn$1bnQ2 ’24Q4 ’24Q2 ’25$1.1bnQ1 ’26$0bnQ2 ’24Q4 ’24Q2 ’25$1.1bnQ1 ’26
Source: SEC filings
Last 12 monthsHUMSector median
Revenue growth+14.1%+7.8%
Operating margin1.8%13.3%
Free cash flow margin0.9%15.9%
Price to earnings39.2x30.2x

Stories on Humana

We haven't written about Humana yet. Follow it, and its first story will show under My stocks on the front page.

Similar companies

Managed Health Care, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
ABBVAbbVie$294.89+1.41%+29.1%$521B
MRKMerck$149.52+2.18%+42.0%$369B
UNHUnitedHealth$406.97−0.96%+23.3%$365B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B